MedTrace Logo

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

NCT00005945 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3054

Last updated 2016-02-23

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia.

PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.

Conditions

Interventions

DRUG

cyclophosphamide

Given IV

DRUG

cytarabine

Given IT

DRUG

daunorubicin hydrochloride

Given IV

DRUG

dexamethasone

Given PO

DRUG

doxorubicin hydrochloride

Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours

DRUG

mercaptopurine

Given PO

DRUG

methotrexate

Given PO and IT

DRUG

pegaspargase

Given IM

DRUG

thioguanine

Given PO

DRUG

vincristine sulfate

Given IV

RADIATION

radiation therapy

Undergo radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Yousif H. Matloub, MD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2007-11-30
Completion
2008-06-30

Countries

  • United States
  • Australia
  • Canada
  • New Zealand
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005945 on ClinicalTrials.gov